Stem Cell News

October 05, 2010

Founders of the Neural Stem Cell Institute Selected to Speak at the World Stem Cell Summit

Contact: Cari Arena  
October 5, 2010
Phone:  518-522-4226

Founders of the Neural Stem Cell Institute
Selected to Speak at the World Stem Cell Summit

Rensselaer, NY — Dr. Sally Temple and Dr. Jeffrey Stern, Founders of the Neural Stem Cell Institute, have been selected to speak at the 2010 World Stem Cell Summit in Detroit next week. More than 1,000 people from 30 countries are expected to attend the event, Monday, Oct. 4, through Wednesday, Oct. 6, at the Marriott Renaissance Center.

This year’s summit will be the sixth annual conference organized by the non-profit Genetics Policy Institute and brings together stem cell scientists, educators, patients and patient advocates, business people and investors, ethicists, policymakers, government representatives and others. More than 150 speakers will be featured.

“I am honored to be participating in this unique meeting that brings together scientists, policy makers, advocates, patients and the public to discuss how stem cell research can bring new therapeutics forward” said Dr. Sally Temple.

Dr. Temple will be a speaker at the session on Tissue Specific Stem Cell Research and Applications and on Progress in Spinal Cord Injury and Dr. Jeffrey Stern will moderate a session entitled “Stem Cell progress Report- Blindness.”

About NSCI: The Neural Stem Cell Institute is a unique organization that produces leading stem cell research to develop new therapies for diseases of the central nervous system (CNS). As the only independent, non-profit stem cell research institute in the US, NSCI aims to harness the power of stem cells to ease suffering caused by injury and disease of the brain, spinal cord and retina. NSCI is led by MacArthur Award winner Dr. Sally Temple who helped discover and define nervous system stem cells. Dr. Temple recruited leading researchers from around the world to help translate discovery research into new therapies for CNS repair including age-related macular degeneration, spinal cord injury, multiple sclerosis and Parkinson’s disease.


< Back to News